SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:RAIN

Rain Therapeutics - RAIN Stock Forecast, Price & News

$4.71
+0.77 (+19.54%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.03
$5.50
50-Day Range
$3.94
$8.01
52-Week Range
$2.15
$17.31
Volume
72,018 shs
Average Volume
42,701 shs
Market Capitalization
$124.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Rain Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.5% Upside
$15.00 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.66) to ($2.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

344th out of 1,075 stocks

Pharmaceutical Preparations Industry

150th out of 537 stocks

RAIN stock logo

About Rain Therapeutics (NASDAQ:RAIN) Stock

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAIN Stock News Headlines

Rain Therapeutics GAAP EPS of -$0.66
See More Headlines
Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAIN Company Calendar

Last Earnings
8/04/2022
Today
10/07/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+218.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-51,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.93 per share

Miscellaneous

Free Float
20,720,000
Market Cap
$124.96 million
Optionable
Not Optionable
Beta
-0.70

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 47)
    Co-Founder, CEO & Chairman
    Comp: $817.59k
  • Dr. Robert C. Doebele M.D. (Age 50)
    Ph.D., Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer
    Comp: $619.14k
  • Dr. Richard P. Bryce (Age 65)
    Exec. VP & Chief Medical Officer
    Comp: $496.25k
  • Mr. Nelson D. Cabatuan (Age 44)
    Sr. VP of Fin. & Admin.
  • Ms. Theresa O'Connell M.S.
    Director of Corp. Devel. & Operations
  • Ms. Jamie S. Blose J.D.
    M.B.A., Pharm.D., Sr. VP & Head of Legal Affairs
  • Mr. Steve Flint M.B.A.
    VP of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Sr. VP & Head of Research
  • Mr. Lucio Tozzi (Age 58)
    Sr. VP of Clinical Operations
  • Ms. Buenaflor Nicolas M.P.H.
    VP, Head Global Drug Safety & Pharmacovigilance













RAIN Stock - Frequently Asked Questions

Should I buy or sell Rain Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAIN shares.
View RAIN analyst ratings
or view top-rated stocks.

What is Rain Therapeutics' stock price forecast for 2022?

5 brokers have issued 12 month price objectives for Rain Therapeutics' shares. Their RAIN share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 218.5% from the stock's current price.
View analysts price targets for RAIN
or view top-rated stocks among Wall Street analysts.

How have RAIN shares performed in 2022?

Rain Therapeutics' stock was trading at $12.88 at the beginning of 2022. Since then, RAIN shares have decreased by 63.4% and is now trading at $4.71.
View the best growth stocks for 2022 here
.

When is Rain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our RAIN earnings forecast
.

How were Rain Therapeutics' earnings last quarter?

Rain Therapeutics Inc. (NASDAQ:RAIN) released its quarterly earnings results on Thursday, August, 4th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.01.

When did Rain Therapeutics IPO?

(RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO.

What is Rain Therapeutics' stock symbol?

Rain Therapeutics trades on the NASDAQ under the ticker symbol "RAIN."

How do I buy shares of Rain Therapeutics?

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Therapeutics' stock price today?

One share of RAIN stock can currently be purchased for approximately $4.71.

How much money does Rain Therapeutics make?

Rain Therapeutics (NASDAQ:RAIN) has a market capitalization of $124.96 million. The company earns $-51,390,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How can I contact Rain Therapeutics?

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.

This page (NASDAQ:RAIN) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.